Novo Nordisk Taps Nanexa's Nanocoating Tech for Long-Acting Obesity Shots
- Novo Nordisk signed a global licensing deal with Swedish biotech Nanexa for its ALD-based PharmaShell platform, which coats drug particles to control release.
- Covers up to five programs in obesity, diabetes and cardiometabolic disease, aiming for monthly/quarterly dosing versus more frequent injections.
- Worth up to €1.165B, with ~€615M upfront/milestones plus royalties; Nanexa shares more than doubled.
💡 Points
Novo again chooses a capital-light platform bet over a big asset buy: licensing unproven ALD nanocoating across five programs to chase Lilly's once-monthly ambitions, since monthly dosing is what keeps patients on therapy once oral GLP-1s and biosimilars start undercutting Wegovy on convenience. Tellingly, ~€615M upfront/milestones against a €1.165B ceiling means Nanexa, not Novo, fronts most of the technical risk until PharmaShell proves out in humans.
Novo does another small deal, this time with drug delivery biotech Nanexa ↗